About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. 

Over the past decade, BCAL has been developing a non-invasive diagnostic technology to assist in the detection of breast cancer, with testing at this time demonstrating excellent performance independent of breast tissue density.

Our Story

A Leading Biotechnology Company

BCAL Diagnostics Limited, an Australian screening and diagnostic company, is dedicated to the early diagnosis of breast cancer, aiming to facilitate early intervention and enhance outcomes for women. Over the past decade, BCAL has engaged in the research and development of non-invasive diagnostic technologies designed to complement existing imaging technologies, such as the mammogram. In the future, the objective is to leverage the proposed technologies into a monitoring and screening tool accessible to women of all ages and backgrounds, regardless of location.

In response to the global burden of over two million new breast cancer cases annually, BCAL has joined forces with Precion Inc. to optimise protocols and procedures for essential clinical studies. This collaboration spans regulatory approvals across various jurisdictions, commercialisation, and market entry points. 

The BCAL laboratory, inaugurated in May 2023 in Sydney, Australia, employs cutting-edge Liquid Chromatography Mass Spectrometry (LCMS) platforms to build on the company's clinical research and leverage progress made by its US commercialisation partner, Precion Inc.

The BCAL laboratory advances clinical research while also serving as a testing site for ongoing and planned clinical validation studies. It is committed to establishing a Quality Management System (QMS) and protocols compliant with ISO 15189 and NPAAC standards, Clinical Laboratory Improvement Amendments (CLIA) regulations for Certification, and the requirements of the Therapeutic Goods Act 1989 (Cth). Founded in 2010, BCAL is headquartered in Sydney and is listed on the Australian Securities Exchange (ASX: BDX).

Our Vision

To deliver global customers an effective, best-in-class, blood-screening technology, benefiting physicians and patients alike.

Our Laboratory


BCAL’s development and clinical service laboratory was officially opened in May 2023.

The laboratory is utilising the latest Liquid Chromatography Mass Spectrometry (LCMS) platforms to continue to advance the findings of the Company’s clinical research to-date and the progress made by BCAL Diagnostics’ US commercialisation partner, Precion Inc.to establish and validate workflows, test protocols and algorithms for our proposed diagnostic technologies.

The BCAL laboratory will also serve as a testing site for the ongoing and planned clinical validation studies and will establish a Quality Management System and protocols to be compliant to ISO 15189 and NPAAC standards, Clinical Laboratory Improvement Amendments (CLIA) regulations for Certification and the requirements of the Therapeutic Goods Act 1989 (Cth).
[email protected]
Suite 506 Level 5, 50 Clarence Street, Sydney NSW 2000

Corporate Governance

BCAL has developed and adopted comprehensive systems of control and accountability as the basis for the administration of corporate governance, based on the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations. The BCAL Diagnostic Board is committed to ensuring the policies and procedures are managed with honesty, integrity, openness and transparency. A strong values based governance structure is key to the foundation and fundamentals of the company. Ensuring it is reflected in all in which we do. For more details please download and read the main policies below:


Members of the Board of Directors represent a wide range of business skills, a deep rooted understanding of the global financial environment and broad experience in biomedical start-ups and the global biomedical marketplace.
Meet Our Team

Dr David Darling

Non-Executive Director

David Darling is a highly credentialed leader and executive who brings a wealth of commercial experience to BCAL from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business focused on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, Mr Darling held senior management positions with Fletcher Challenge. ​

Mr Darling has a background as a scientist with a specialty in genetics and has more than three decades of experience in developing and commercialising life sciences and biotechnology products.

Mark Burrows AO

Independent Non-Executive Director

Mark Burrows AO, with a distinguished global career in investment banking, transitioned into advocating private sector engagement for sustainable development and green finance evolution. Mark held senior advisory roles with UNEP, UNDP, The Green Finance Initiative in London, and the G20 Sustainability Group. Presently, he serves on the Asian Board of the Nature Conservancy, embodying his commitment to environmental initiatives and sustainable practices.

Jayne Shaw

Co-Founder and Executive Chair

Jayne Shaw is the Executive Chair and co-founder of BCAL Diagnostics. She is a qualified and registered nurse in the UK, and on arrival in Australia she became Director of Nursing and Chief Executive Officer of two private hospitals. Founding a consulting business, later acquired by Healthsouth, she co-founded Vision Group—an ASX-listed Ophthalmic Doctor equity model. With diverse roles on private healthcare boards, she co-owns Sydney Breast Clinic. Holding current board positions at The Citadel Group, Ellerston JAADE Australian Private Assets Fund, Mable Technologies, and Corum Group. Jayne also serves as a Non-Executive Director at Pinnacle Charitable Foundation and Prospection.

The Hon Ron Phillips (AO)


After 15 years in the NSW Parliament, including roles as Minister for Health and Deputy Leader of the Opposition, Ron forged a thriving consulting business in Health and Aged Care. Formerly co-owner and Managing Director of Sydney Breast Clinic, later sold to Healthscope, he now chairs the Sydney Local Health District and serves as Director on Westmead IVF.

Jonathan Trollip

Independent Non-Executive Director

Jonathan, an Independent Non-Executive Director, brings over 30 years of global expertise in commercial, corporate governance, and law. He currently chairs ASX-listed entities, including Global Value Fund Ltd, Plato Income Maximizer Limited, and Spheria Emerging Companies Limited. Jonathan serves as a non-executive director for Kore Potash Limited on LSE, JSE, and ASX. His extensive background includes leadership roles at Meridian International Capital Limited and Herbert Smith Freehills. A Fellow of the Australian Institute of Company Directors, he previously chaired Future Generation Investment Company Ltd, Antipodes Global Investment Company Ltd, and Spicers Limited.

Dr John Hurrell

Non-Executive Director and Consultant

Dr Hurrell has developed and successfully commercialised multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including successful life science companies based on university developed technologies. Most notably Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest’s subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and successfully gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics.

Sign-Up To Receive The Latest Updates
2024 © BCAL Diagnostics
Privacy Policy
Terms & Conditions
Made by Eightball Media